within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EB03_Afatinib;

model Afatinib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.92,
    Cl = 8.055555555555556e-06,
    adminDuration = 600,
    adminMass = 50 / 1000000,
    adminCount = 1,
    Vd = 0.45,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004,
    Tlag = 24.0,
    Vdp = 1.75,
    k12 = 5.444444444444446e-06,
    k21 = 5.444444444444446e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Afatinib</td></tr><tr><td>ATC code:</td><td>L01EB03</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>50</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>450</td><td>L</td></tr>
    <tr><td>clearance:</td><td>29</td><td>L/h</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Afatinib is an orally administered, irreversible inhibitor of the ErbB family of tyrosine kinases, including EGFR (epidermal growth factor receptor). It is primarily used for the treatment of non-small cell lung cancer (NSCLC) with EGFR mutations and is approved for clinical use today.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in adult patients with advanced solid tumors or non-small cell lung cancer under fasting conditions.</p><h4>References</h4><ol><li><p>Wind, S, et al., &amp; Stopfer, P (2017). Clinical Pharmacokinetics and Pharmacodynamics of Afatinib. <i>Clinical pharmacokinetics</i> 56(3) 235–250. DOI:<a href=\"https://doi.org/10.1007/s40262-016-0440-1\">10.1007/s40262-016-0440-1</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27470518/\">https://pubmed.ncbi.nlm.nih.gov/27470518</a></p></li><li><p>Nakao, K, et al., &amp; Atagi, S (2019). Population pharmacokinetics of afatinib and exposure-safety relationships in Japanese patients with EGFR mutation-positive non-small cell lung cancer. <i>Scientific reports</i> 9(1) 18202–None. DOI:<a href=\"https://doi.org/10.1038/s41598-019-54804-9\">10.1038/s41598-019-54804-9</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/31796841/\">https://pubmed.ncbi.nlm.nih.gov/31796841</a></p></li><li><p>Freiwald, M, et al., &amp; Staab, A (2014). Population pharmacokinetics of afatinib, an irreversible ErbB family blocker, in patients with various solid tumors. <i>Cancer chemotherapy and pharmacology</i> 73(4) 759–770. DOI:<a href=\"https://doi.org/10.1007/s00280-014-2403-2\">10.1007/s00280-014-2403-2</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/24522402/\">https://pubmed.ncbi.nlm.nih.gov/24522402</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EB03 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Afatinib;
